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Polish epidemiological and statistical data, and a systematic review (proportion of 
patients treated with antipsychotic drugs who withdrew because of adverse events). 
Current and predicted market shares were assessed on the basis of present sales level 
data. RESULTS: In the ﬁ rst scenario, NHF expenditures on atypical antipsychotic 
drugs will increase by: 13 mln PLN in 2010, 20 mln PLN in 2011 and 26 mln PLN 
in 2012. In the second scenario of no sertindole reimbursement NHF expenditures on 
atypical antipsychotic drugs will increase by: 11 mln PLN in 2010, 18 mln PLN in 
2011 and 23 mln PLN in 2012. From patient’s perspective, expenditures will increase 
in 2010–2012 by 0.9 mln PLN 1.3 mln PLN and 1.7 mln respectively in scenario with 
sertindole reimbursement, while in a second scenario costs will increase in 2010–2012 
by 1.1 mln PLN, 1.6 mln PLN and 2.0 mln PLN respectively. The 2009 weighted 
average exchange rate of Polish National Bank was c1 = PLN 4.3273. CONCLU-
SIONS: Reimbursement of sertindole would result in a minor increase in Polish NHF 
expenditures. Simultaneously, it would enlarge the scope of accessible therapies for 
patients intolerant to at least one other antipsychotic agent.
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OBJECTIVES: Generic medicines are generally considerably less expensive than 
branded products and their endorsement can lead to substantial savings in costs. The 
main objective of the study was to calculate potential cost savings that can be gener-
ated by generic substitution of antidepressants within the private health care sector of 
South Africa. METHODS: Data on computerised medicine claims of patients receiving 
one or more antidepressants during three consecutive years (i.e. 2004, 2005 and 2006) 
were elicited from a South African pharmaceutical beneﬁ t management company. a 
non-experimental, quantitative, retrospective drug utilization review was conducted 
and data were analyzed using the Statistical Analysis System® programme. Potential 
cost savings deﬁ ned as the collective amount that could be saved annually by substitut-
ing the average price of innovator active substances for that of generic equivalent(s) 
were computed for criteria-eligible substances in the study population. All costs are 
expressed in $U.S. RESULTS: A total of 292,071 items (N = 5,982,869) on 273,673 
prescriptions (N = 5,213,765) at a total cost of $8,652,289.48 (N = $207,316,483.10) 
were included in the study. Generic products constituted 58.7% (n = 292,071) of all 
antidepressants claimed, at a total cost of 28.2% (N = $207,316,483.10) of all 
incurred costs. With total substitution of the average price of all criteria-eligible 
innovators, a potential saving of 9.3% (N = $8,652,289.48) of the actual antidepres-
sant cost over the study period, was calculated. CONCLUSIONS: In developing 
countries with limited health care budgets, such as South Africa, generic substances 
can be cost-saving treatment alternatives. Health care professionals, third-party 
payers, and patients all have fundamental roles to play in order to encourage greater 
use of generics. Medicine expenditure can thereby be reduced and access to scarce 
resources increased, in order to meet the pressing health care needs within South 
Africa.
PMH11
BUDGET IMPACT ANALYSIS OF AMISULPRIDE IN TREATMENT OF 
SCHIZOPHRENIA IN POLAND
Wilk D1, Rutkowski J1, Dziewiatka M1, Lis J2, Glasek M2, Plisko R1
1HTA Consulting, Krakow, Poland; 2Sanoﬁ -Aventis Poland, Warszawa, Poland
OBJECTIVES: To estimate the impact of amisulpride continued reimbursement in 
schizophrenia treatment on payer’s budget in Poland. METHODS: The analysis was 
performed in 5-year time horizon from the payer (National Health Fund, NHF) 
perspective and payer + patient perspective. Only costs of medicines were included. 
On the base of IMS Health Poland sale data for years 2005–2010 linear regression 
was conducted to predict consumption and prevalence of antipsychotics in Poland. 
Cost data of medicines were obtained from Ministry of Health and medicine portals 
in case of lack of reimbursement. One-way sensitivity analysis were performed for the 
key input parameters. RESULTS: From the payer perspective, cost of amisulpride is 
approximately c7.13 million in 2010 and c9.15 million in 2014 and it represents from 
4.62% in 2010 to 4.28% in 2014 of the total cost of schizophrenia treatment esti-
mated at approximately c154.22 million in 2010 and c213.87 million in 2014. From 
the payer + patient perspective, cost of amisulpride is approximately c7.26 million in 
2010 and c9.32 million in 2014 and it represents from 4.01% in 2010 to 3.85% of 
the total cost of schizophrenia treatment estimated at approximately c181.11 million 
in 2010 and c241.81 million in 2014. Increase of NHF and patients expenses is related 
to an increase of antipsychotics sales over a span of the next ﬁ ve years caused by 
expanding awareness of schizophrenia and the importance of treatment. CONCLU-
SIONS: Our ﬁ ndings suggest that the cost of treatment with amisulpride are at a 
reasonable level and represent a small proportion of the total costs of schizophrenia 
treatment both from the payer perspective and common payer + patient perspective. 
The declining trend in the share of amisulpride cost in total cost of schizophrenia is 
noticeable. Amisulpride is an alternative therapeutic option of schizophrenia treatment 
in Poland and its reimbursement from public funds is justiﬁ ed.
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OBJECTIVES: To compare the health care costs 6 months prior to and 6 months after 
initiation of pregabalin in generalized anxiety disorder (GAD) patients in Sweden. 
METHODS: This was a retrospective longitudinal database study of GAD patients from 
the South-West region of Sweden (1.5 million inhabitants). Individual patient data on 
health care visits (outpatient, inpatient, primary care), costs, mortality and diagnoses 
were included from year 2000. Data from the Swedish Prescribed Drug Register were 
included from July 1, 2005 until December 31, 2007. Patients with a GAD (ICD-10 
F41.1) diagnosis and who initiated pregabalin treatment in 2006 were included. Health 
care utilization was measured six months before and six months after pregabalin initia-
tion. Patients with 2 or more prescriptions of benzodiazepines six months prior to 
pregabalin initiation were categorized as benzodiazepine patients. Non-parametric sta-
tistical tests (Mann-Whitney) were used for the cost and resource use comparisons. 
RESULTS: A total of 149 patients met the inclusion criteria, of whom 99 used benzo-
diazepines prior to pregabalin treatment. The number of in-patient (P < 0.05) and 
primary care (P < 0.05) visits signiﬁ cantly decreased in the 6-month period following 
pregabalin initiation. There was also a statistically signiﬁ cant reduction (p = 0.0004) in 
overall health care costs from SEK 71,000 (c7,408) to SEK 45,000 (c4,695). Among 
the benzodiazepine users (n = 99), the number of in-patient visits (p = 0.0213), days in 
hospital (p = 0.0026) and primary care visits (p = 0.0121) were all statistically signiﬁ -
cantly reduced following pregabalin initiation. The reduction in total cost (from SEK 
79,000 to SEK 43,000; c8,243 to c4,486) among the users of benzodiazepines was also 
statistically signiﬁ cant (p = 0.0001). The decrease in total cost, in all patients as well as 
benzodiazepine treated, was to a large extent explained by the decrease in in-patient 
costs. CONCLUSIONS: Initiating treatment with pregabalin in GAD patients signiﬁ -
cantly reduced health care utilization and costs during the following 6 months.
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OBJECTIVES: There is accumulating evidence of sub-therapeutic second-generation 
antipsychotic (SGA) dosing for patients diagnosed with bipolar disorder, leading to 
suboptimal control of disease and higher overall treatment costs. The objectives of 
this study were to identify Medicaid bipolar patients receiving clinically effective doses 
of SGAs and compare their medical costs. METHODS: Patients with bipolar disorder 
taking an oral SGA (aripiprazole, olanzapine, quetiapine, risperidone or ziprasidone) 
were identiﬁ ed in Medicaid claims databases (2005–2008) from 8 US states. Patients 
were followed for 18 months (6-month pre-index period during which patients did 
not receive an SGA, followed by a 12-month post-index utilization period to determine 
total costs). For patients on recommended dosing, costs were compared using a gen-
eralized linear model with a gamma distribution and log-link function. Baseline 
covariates (age, gender, race, pre-index costs, Charlson co-morbidity score, and spe-
ciﬁ c psychiatric co-morbidities) were adjusted for. Ziprasidone-treated patients com-
prised the reference group. RESULTS: A total of 2446 patients met inclusion criteria, 
with 45% (N = 1102) taking clinically effective doses by day 61 of their follow-up 
period. Patients on quetiapine had the lowest percentage of effective dosing at 26% 
(N = 280/1072). Other results were aripiprazole 77% (N = 336/448), olanzapine 52% 
(N = 118/226), risperidone 50% (N = 238/474), and ziprasidone 58% (N = 130/226). 
Regression analyses indicated that mental health-related prescription costs (P < 0.01) 
and all-prescription costs (P < 0.01) were statistically signiﬁ cantly lower for the ris-
peridone group compared to the ziprasidone group. There were no signiﬁ cant differ-
ences between the groups for total mental health-related costs or total all-cause costs 
(includes prescription and medical services). CONCLUSIONS: Less than half of the 
patients in this sample were prescribed clinically recommended doses 2 months after 
their initial start. Among patients using recommended doses, while those on risperi-
done had lower prescription costs, there were no signiﬁ cant differences for total costs 
compared to patients taking ziprasidone.
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OBJECTIVES: This study investigates the health care costs of adverse events (AE) 
associated with treatment of bipolar disorder with two atypical antipsychotics (AA): 
aripiprazole (ARI) and Olanzapine (OLA). METHODS: It was performed a cost 
analysis through a markov model considering the following health states: no existence 
